OMCL - Omnicell, Inc.
NASDAQ
->
Healthcare
->
Health Information Services
Mountain View,
United States
Type: Equity
OMCL price evolution
OMCL
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $467.97 | $446.84 | $399.46 | $340.41 |
| Short term investments | ||||
| Net receivables | $252.03 | $272.58 | $273.9 | $322.07 |
| Inventory | $110.1 | $116.14 | $130.58 | $141.16 |
| Total current assets | $927.57 | $913.75 | $881.36 | $934.97 |
| Long term investments | $42.95 | $41.63 | $35.04 | $32.74 |
| Property, plant & equipment | $133.59 | $132.32 | $130.91 | $126.6 |
| Goodwill & intangible assets | $946.98 | $953.19 | $962.23 | $969.58 |
| Total noncurrent assets | $1299.31 | $1307.82 | $1312.51 | $1315.87 |
| Total investments | $42.95 | $41.63 | $35.04 | $32.74 |
| Total assets | $2226.88 | $2221.57 | $2193.87 | $2250.84 |
| Current liabilities | ||||
| Accounts payable | $45.03 | $49.92 | $47.19 | $63.41 |
| Deferred revenue | $180.36 | $180.04 | $173.35 | $185.74 |
| Short long term debt | ||||
| Total current liabilities | $367.79 | $369.36 | $370.16 | $453.97 |
| Long term debt | $569.66 | $601.73 | $603.62 | $604.2 |
| Total noncurrent liabilities | $670.13 | $664.78 | $660.15 | $654.33 |
| Total debt | $603.57 | $601.73 | $603.62 | $604.2 |
| Total liabilities | $1037.92 | $1034.14 | $1030.31 | $1108.3 |
| Shareholders' equity | ||||
| Retained earnings | $370.36 | $384.73 | $379.18 | $375.73 |
| Other shareholder equity | $1188.95 | -$17.13 | -$14.18 | -$15.61 |
| Total shareholder equity | $1188.95 | $1187.44 | $1163.57 | $1142.54 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $467.97 | $330.36 | $349.05 | $485.93 |
| Short term investments | ||||
| Net receivables | $252.03 | $299.47 | $240.89 | $190.12 |
| Inventory | $110.1 | $147.55 | $119.92 | $96.3 |
| Total current assets | $927.57 | $881.81 | $780.7 | $829.41 |
| Long term investments | $42.95 | $32.92 | $18.39 | $22.16 |
| Property, plant & equipment | $133.59 | $132.01 | $119.69 | $114.19 |
| Goodwill & intangible assets | $946.98 | $977.18 | $1016.52 | $667.52 |
| Total noncurrent assets | $1299.31 | $1328.95 | $1361.79 | $995.09 |
| Total investments | $42.95 | $32.92 | $18.39 | $22.16 |
| Total assets | $2226.88 | $2210.76 | $2142.5 | $1824.5 |
| Current liabilities | ||||
| Accounts payable | $45.03 | $63.39 | $71.51 | $40.31 |
| Deferred revenue | $180.36 | $156.33 | $132.39 | $105.73 |
| Short long term debt | $488.15 | |||
| Total current liabilities | $367.79 | $428.45 | $876.16 | $276.42 |
| Long term debt | $569.66 | $566.57 | $39.91 | $516.1 |
| Total noncurrent liabilities | $670.13 | $652.17 | $119.65 | $580.58 |
| Total debt | $603.57 | $605.98 | $528.06 | $516.1 |
| Total liabilities | $1037.92 | $1080.62 | $995.81 | $857 |
| Shareholders' equity | ||||
| Retained earnings | $370.36 | $390.73 | $368.57 | $290.72 |
| Other shareholder equity | $1188.95 | -$17.09 | -$8.41 | -$5.52 |
| Total shareholder equity | $1188.95 | $1130.14 | $1146.69 | $967.5 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $258.85 | $298.66 | $298.97 | $290.63 |
| Cost of revenue | $166.7 | $164.53 | $165.6 | |
| Gross Profit | $105.4 | $131.96 | $134.44 | $125.03 |
| Operating activities | ||||
| Research & development | $24.28 | $23.14 | $22.88 | |
| Selling, general & administrative | $103.97 | $103.56 | $125.11 | |
| Total operating expenses | $128.77 | $128.25 | $126.69 | $147.99 |
| Operating income | $3.71 | $7.75 | -$22.96 | |
| Income from continuing operations | ||||
| EBIT | $3.71 | $7.75 | -$22.96 | |
| Income tax expense | -$4.14 | $1.83 | $8.76 | -$6.18 |
| Interest expense | $4.85 | -$3.67 | -$4.46 | -$1.78 |
| Net income | ||||
| Net income | -$14.38 | $5.55 | $3.45 | -$15 |
| Income (for common shares) | $5.55 | $3.45 | -$15 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1147.11 | $1295.95 | $892.21 | |
| Cost of revenue | $706.96 | $478.92 | ||
| Gross Profit | $496.84 | $588.99 | $413.29 | |
| Operating activities | ||||
| Research & development | $104.97 | $70.16 | ||
| Selling, general & administrative | $486.34 | $307.61 | ||
| Total operating expenses | $531.71 | $591.31 | $377.77 | |
| Operating income | -$2.32 | $35.53 | ||
| Income from continuing operations | ||||
| EBIT | -$2.32 | $35.53 | ||
| Income tax expense | $0.26 | -$8.1 | -$2.85 | |
| Interest expense | $14.76 | $0.13 | $6.18 | |
| Net income | ||||
| Net income | -$20.37 | $5.65 | $32.19 | |
| Income (for common shares) | $5.65 | $32.19 | ||
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $5.55 | $3.45 | -$15 | |
| Operating activities | ||||
| Depreciation | $23.55 | $24.06 | $24.22 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.98 | $14.09 | $14.04 | |
| Total cash flows from operations | $57.01 | $72.9 | $12.77 | |
| Investing activities | ||||
| Capital expenditures | -$14.19 | -$14.82 | -$10.14 | |
| Investments | ||||
| Total cash flows from investing | -$55.02 | -$14.19 | -$14.82 | -$13.64 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.83 | $3.09 | $12.11 | |
| Net borrowings | ||||
| Total cash flows from financing | $23.42 | $2.83 | $3.6 | $3.86 |
| Effect of exchange rate | -$1.35 | -$0.61 | -$0.03 | $0.18 |
| Change in cash and equivalents | $148.14 | $45.03 | $61.66 | $3.17 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5.65 | $77.85 | $32.19 | |
| Operating activities | ||||
| Depreciation | $99.17 | $84.93 | $71.59 | |
| Business acquisitions & disposals | $2.07 | -$354.16 | -$225 | |
| Stock-based compensation | $68.25 | $53.16 | $44.7 | |
| Total cash flows from operations | $77.78 | $231.81 | $185.87 | |
| Investing activities | ||||
| Capital expenditures | -$60.74 | -$58.34 | -$54.87 | |
| Investments | ||||
| Total cash flows from investing | -$55.02 | -$58.67 | -$412.5 | -$279.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$12.03 | $67.35 | $52.52 | |
| Net borrowings | $408.49 | |||
| Total cash flows from financing | $23.42 | -$20.95 | $47.36 | $456.27 |
| Effect of exchange rate | -$1.35 | -$0.94 | -$0.97 | $0.44 |
| Change in cash and equivalents | $148.14 | -$2.79 | -$134.3 | $362.71 |
News
|
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down
Zacks via Yahoo Finance
12 Feb 2024
|
|
Analysts Have Been Trimming Their Omnicell, Inc. (NASDAQ:OMCL) Price Target After Its Latest Report
Simply Wall St. via Yahoo Finance
11 Feb 2024
|
|
Omnicell, Inc. (NASDAQ:OMCL) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
9 Feb 2024
|
|
Omnicell: Q4 Earnings Snapshot
Washington Post
8 Feb 2024
|
|
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
Zacks via Yahoo Finance
8 Feb 2024
|
|
Omnicell (OMCL) Gains From Innovation Amid Cost Pressure
Zacks via Yahoo Finance
2 Jan 2024
|
|
Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?
Simply Wall St. via Yahoo Finance
15 Dec 2023
|
|
Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail
Zacks via Yahoo Finance
6 Dec 2023
|
|
Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes
Zacks via Yahoo Finance
16 Nov 2023
|
|
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In...
Benzinga
2 Nov 2023
|
Fundamentals
| Market cap | $1.24B |
|---|---|
| Enterprise value | $1.37B |
| Shares outstanding | 45.47M |
| Revenue | $1.15B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$20.37M |
| Revenue Q/Q | -13.04% |
| Revenue Y/Y | N/A |
| P/E ratio | -60.82 |
|---|---|
| EV/Sales | 1.20 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.08 |
| P/B ratio | InfinityT |
| Book/Share | 0.00 |
| Cash/Share | 10.29 |
| EPS | -$0.45 |
|---|---|
| ROA | -0.92% |
| ROE | -1.74% |
| Debt/Equity | 0.87 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.52 |
| Quick ratio | 2.22 |